Becton, Dickinson and Company (BIT:1BDX)
Italy
· Delayed Price · Currency is EUR 147.00
0.00 (0.00%)
At close: Jun 26, 2025, 5:30 PM CET
Revenue by Product
Fiscal year is October - September.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2012 - 2019 |
Medication Delivery Solutions | 4.43B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medication Delivery Solutions Growth | 3.87% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharmaceutical Systems | 2.27B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharmaceutical Systems Growth | 0.44% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Biosciences | 1.51B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Biosciences Growth | -3.41% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | -67.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medication Management Solutions | 3.30B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medication Management Solutions Growth | 10.49% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Surgery | 1.49B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Surgery Growth | 1.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Peripheral Intervention | 1.93B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Peripheral Intervention Growth | 1.99% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Urology and Critical Care | 1.55B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Urology and Critical Care Growth | 4.09% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medical | 10.07B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medical Growth | 11.41% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Life Sciences | 5.19B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Life Sciences Growth | -0.08% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Interventional | 4.98B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Interventional Growth | 2.45% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | -67.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is October - September.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2012 - 2019 |
Other | -2.88B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medical Operating Income | 2.74B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medical Operating Income Growth | 31.39% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Life Sciences Operating Income | 1.60B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Life Sciences Operating Income Growth | 1.55% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | -2.88B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Interventional Operating Income | 1.42B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Interventional Operating Income Growth | 17.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|